Journal article · 2025 · Open access
OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)
Annals of the Rheumatic Diseases, 84, 193–194 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.05.243
In brief
“OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)” is a 2025 journal article by R. Aymon and 25 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 5 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 5
- Most cited in
- 2026 (3)
- Authors
- 26
Abstract
Background: Regulatory authorities issued precautionary recommendations on the use of Janus kinase inhibitors (JAKi) following the ORAL Surveillance trial [1], which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi). While these findings have influenced clinical guidance, there is still limited real-world evidence on malignancy risks associated with JAKi treatment. Objectives: To assess the incidence of cancer in rheumatoid arthritis (RA) patients treated with JAKi, compared to other biologic disease modifying anti-rheumatic drugs (bDMARDs), using data from a large, multi-country, real-world population. Methods: We studied patients from 13 RA registers across Europe and Québec, starting JAKi, TNFi -inhibitors (TNFi) or bDMARDs with other modes of action (OMA). Outcomes of interest were categorized into cancer excluding non-melanoma skin cancer (NMSC); and NMSC cases. Cancers were linked to treatments within 5 years of cessation or until follow-up loss, death, or study end, whichever came first. Incidence rates (IR) per 100 patient-years (PY) with 95% confidence intervals (CI) were computed. Poisson regression, with propensity score weighting (including country, disease-, and patient-characteristics, and comorbidities, see Figure 1), was used to obtain adjusted incidence rate ratios (aIRR), with 95% CI. A sub-analysis was performed on patients aged ≥ 50 years and ≥ 1 cardiovascular risk factor, mimicking the "ORAL Surveillance" trial inclusion criteria (high risk cohort). Results: Over the 53'169 treatment initiations considered in 33'127 patients, 638 cancers excluding NMSC and 219 NMSC were reported. Crude incidence of cancer excluding NMSC was lower for TNFi (2.2/1000 PY) than for JAKi (2.9/1000 PY) and OMA (3.1/1000 PY). The adjusted Poisson regression found no significant difference in the incidence of cancer excluding NMSC (aIRR = 1.10; 95% CI [0.89; 1.37]) or NMSC (aIRR = 1.12; 95% CI [0.78; 1.60]) between JAKi and TNFi, nor between JAKi and OMA (aIRR = 1.07; 95% CI [0.86; 1.32] and aIRR=0.79; 95% CI [0.54; 1.15] respectively). The high risk cohort accounted for 39.4% of treatment courses and had a higher incidence of cancer in each treatment group (OMA: 4.1/1000 PY, JAKi: 4.2/1000 PY, TNFi: 3.2/1000 PY). Similarly to the overall population, no significant difference in the incidence of cancer excluding NMSC (aIRR = 1.16; 95% CI [0.86; 1.57]) and NMSC (aIRR = 1.15; 95% CI [0.71; 1.84]) was observed between JAKi and TNFi, nor between JAKi and OMA (aIRR = 1.09; 95% CI [0.81; 1.47] and aIRR=0.92; 95% CI [0.58; 1.46] respectively). Conclusion: In this real-world study, including 13 RA registers and all currently available JAKi, we did not find a significantly higher risk of cancer excluding…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Aymon, R., Mongin, D., Gilbert, B. T. P., Guemara, R., Choquette, D., Codreanu, C., Coupal, L., Flouri, I. D., Fritsch-Stork, R. D. E., Giacomelli, R., Huschek, D., Iannone, F., Kvien, T. K., Otero-Varela, L., Nordström, D., Pavelká, K., Pombo‐Suárez, M., Provan, S. A., Rotar, Z., . . . Lauper, K. (2025). OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY). Annals of the Rheumatic Diseases, 84, 193–194. https://doi.org/10.1016/j.ard.2025.05.243
MLA 9
Aymon, R., et al. “OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY).” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 193–194. https://doi.org/10.1016/j.ard.2025.05.243.
Chicago
Aymon, R., Denis Mongin, Benoît Thomas P. Gilbert, Romain Guemara, D. Choquette, Cătălin Codreanu, Louis Coupal, et al. 2025. “OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY).” Annals of the Rheumatic Diseases 84: 193–194. https://doi.org/10.1016/j.ard.2025.05.243.
Harvard
Aymon, R. et al. (2025) ‘OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)’, Annals of the Rheumatic Diseases, 84, pp. 193–194. doi:10.1016/j.ard.2025.05.243.
IEEE
R. Aymon et al., “OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY),” Annals of the Rheumatic Diseases, vol. 84, pp. 193–194, 2025, doi: 10.1016/j.ard.2025.05.243.
BibTeX
@article{aymon2025cancer,
title = {{OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)}},
author = {Aymon, R. and Mongin, Denis and Gilbert, Benoît Thomas P. and Guemara, Romain and Choquette, D. and Codreanu, Cătălin and Coupal, Louis and Flouri, Irini D. and Fritsch-Stork, Ruth D. E. and Giacomelli, R. and Huschek, D. and Iannone, Florenzo and Kvien, Tore Kristian and Otero-Varela, Lucía and Nordström, Dan and Pavelká, Karel and Pombo‐Suárez, Manuel and Provan, Sella Aarrestad and Rotar, Z. and Sidiropoulos, Prodromos and Vieira‐Sousa, Elsa and Strangfeld, A. and Závada, Jakub and Courvoisier, Delphine Sophie and Finckh, A. and Lauper, Kim},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {193--194},
doi = {10.1016/j.ard.2025.05.243},
url = {https://doi.org/10.1016/j.ard.2025.05.243}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tofacitinib
- cancer incidence
- non-melanoma skin cancer
- TNF-alpha inhibitors
- biologic DMARDs
- propensity score weighting
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Aymon, R., Mongin, D., Gilbert, B. T. P., Guemara, R., Choquette, D., Codreanu, C., Coupal, L., Flouri, I. D., Fritsch-Stork, R. D. E., Giacomelli, R., Huschek, D., Iannone, F., Kvien, T. K., Otero-Varela, L., Nordström, D., Pavelká, K., Pombo‐Suárez, M., Provan, S. A., Rotar, Z., . . . Lauper, K. (2025). OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY). Annals of the Rheumatic Diseases, 84, 193–194. https://doi.org/10.1016/j.ard.2025.05.243
How many times has this paper been cited?
5 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
R. Aymon, Denis Mongin, Benoît Thomas P. Gilbert, Romain Guemara, D. Choquette, Cătălin Codreanu, Louis Coupal, Irini D. Flouri, Ruth D. E. Fritsch-Stork, R. Giacomelli, D. Huschek, Florenzo Iannone and 14 more.
What is the DOI of this paper?
10.1016/j.ard.2025.05.243, permanently at https://doi.org/10.1016/j.ard.2025.05.243. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.